News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
New cancer drugs could treat lethal resistant prostate cancers
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
Eminent cancer researchers elected to Royal Society Fellowship
Two world-leading scientists at The Institute of Cancer Research, London, have been made Fellows of the Royal Society – one of the greatest honours in UK science.
Top breast cancer scientist recognised by the Academy of Medical Sciences
Professor Clare Isacke has been elected to the Academy of Medical Sciences in recognition of her outstanding contribution to the advancement of cancer research.
ICR gains major award for supporting women in science
The Institute of Cancer Research, London, is committed to creating a supportive work environment, providing good career support for both women and men, and to remove any unnecessary barriers to career progression. Our efforts to address gender inequality have been recognised with a prestigious Athena SWAN Silver Award.
ICR runners’ success at the London Marathon
As in previous years, The Institute of Cancer Research, London, had an inspiring team of runners taking part in the prestigious London Marathon. This year, #teamICR comprised of 25 runners who are set to raise an outstanding amount of money that will help fund our research.
Early blood test predicts response to advanced prostate cancer treatment
An early blood test could help doctors identify which patients will benefit from treatment for advanced prostate cancer, according to a new study.
Immunotherapy is first to show survival benefit in head and neck cancer
The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.
Breast cancer can ‘reprogram’ its metabolism to resist hormone therapy
Cells from the most common form of breast cancer can reprogram their metabolism to help resist hormone treatments and become more aggressive, a new study shows.
London Cancer Hub cited in report on innovation districts in capital
A report into London’s new knowledge economy highlights plans for The London Cancer Hub – which aims to be one of the world’s top life-science campuses specialising in cancer – as a prime example of an ‘innovation district’.
Team ICR will be running the London Marathon
A team of 25 runners will be representing The Institute of Cancer Research, London, in the 2016 London Marathon. Their inspiring efforts will help support our world-leading cancer research.
Cancer cells turn healthy cells to the ‘dark side’
Cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread, a major new study reports.
Watch: How cancers turn healthy cells to the ‘dark side’
Through images and video, we explain new research that shows cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread.
